|
시장보고서
상품코드
1786775
세계의 리소좀 축적 질환 치료 시장 - 규모, 점유율, 동향, 산업 분석 보고서 : 질환 유형별, 치료 유형별, 최종 사용자별, 지역별 시장 예측(2025-2034년)Lysosomal Storage Disease Treatment Market Size, Share, Trends, & Industry Analysis Report By Disease Type, By Type of Therapy, By End User, and By Region - Market Forecast, 2025-2034 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최근 조사에 따르면 세계의 리소좀 축적 질환 치료 시장 규모는 2034년까지 68억 달러에 달할 전망입니다. 이 조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
리소좀 축적 질환 치료시장은 제약기업과 연구개발기관이 희귀한 유전성 질환에 대처하기 위한 새로운 치료법을 개발하는 가운데 꾸준한 진전을 보이고 있습니다. 인지도 향상, 환자 옹호 증가, 지원 규제 프레임워크는 의약품 승인을 가속화하고 혁신적인 치료법에 대한 액세스를 개선하는 데 도움이 됩니다.
생명공학과 맞춤형 의료에 대한 투자가 증가하고 시장의 초점은 대증 치료에서 장기적인 질병 관리 및 잠재적인 치료법 개발로 옮겨가고 있습니다. 이 진화는 고셰병, 파브리병, 폼페병 등의 질병에 대한 환자의 결과를 개선하고 보다 효과적이고 치밀한 치료법을 제공하는 것에 대한 강한 뒷받침을 반영합니다.
리소좀 축적 질환 치료 시장 보고서 하이라이트
질병 유형별로 고셰병이 2024년 시장을 석권했습니다. 이것은 세계적으로 널리 보급되고 있으며 확립된 치료 생태계가 존재한다는 배경에 있습니다.
치료 유형별로 효소 보충 요법(ERT) 분야가 2024년 시장을 독점했습니다. 이것은 다양한 리소좀 축적 질환의 관리에서 채용이 증가하고 있는 것이 배경에 있습니다.
최종 사용자별로는 효소보충요법이나 줄기세포를 이용한 치료 등 전문적인 개입을 제공하는 병원 분야가 2024년 시장을 독점했습니다.
북미는 희소유전성 질환의 치료를 진행하는 생명공학기업과 제약기업의 강한 존재감으로 2024년 세계의 리소좀 축적 질환 치료 시장에서 36.98%의 대부분의 점유율을 차지했습니다.
아시아태평양은 6.13% 시장 점유율을 차지했는데, 이는 의료 인프라의 지속적인 개선과 고급 진단 능력에 대한 접근으로 인한 것입니다.
세계 주요 시장 기업은 Alexion Pharmaceuticals, Inc., Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc., Eli Lilly and Company, Johnson & Johnson(Actelion Pharmaceuticals Ltd.), Merck & Co., Inc., Novartis AG, Pfizer Inc. Inc., Takeda Pharmaceutical Company Limited(Shire Plc), Chiesi Farmaceutici SpA, Orphazyme A/S, Protalix BioTherapeutics, Inc., Ultragenyx Pharmaceutical Inc. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 리소좀 축적 질환 치료 시장 인사이트
- 시장 현황
- 리소좀 축적 질환 치료 시장 역학
- 성장 촉진요인과 기회
- 희소 유전성 질환의 발생률의 상승
- 효소 보충 요법(ERT)의 진보
- 성장 억제요인과 과제
- 고액의 치료비와 한정된 상환
- 성장 촉진요인과 기회
- PESTLE 분석
- 리소좀 축적 질환 치료 시장 동향
- 밸류체인 분석
제5장 세계의 리소좀 축적 질환 치료 시장 : 질환 유형별
- 주요 조사 결과
- 소개
- 고셰병
- 파브리병
- 폼페병
- 뮤코다당증
- 기타
제6장 세계의 리소좀 축적 질환 치료 시장 : 치료 유형별
- 주요 조사 결과
- 소개
- 효소 보충 요법
- 줄기세포요법
- 기질 감소 요법
- 기타
제7장 세계의 리소좀 축적 질환 치료 시장 : 최종 사용자별
- 주요 조사 결과
- 소개
- 병원
- 클리닉
- 기타
제8장 세계의 리소좀 축적 질환 치료 시장 : 지역별
- 주요 조사 결과
- 소개
- 리소좀 축적 질환 치료 시장 평가 : 지역별, 2020-2034년
- 북미
- 북미 : 질환 유형별, 2020-2034년
- 북미 : 치료 유형별, 2020-2034년
- 북미 : 최종사용자별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 질환 유형별, 2020-2034년
- 유럽 : 치료 유형별, 2020-2034년
- 유럽 : 최종사용자별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 질병 유형별, 2020-2034년
- 아시아태평양 : 치료 유형별, 2020-2034년
- 아시아태평양 : 최종 사용자별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 질병 유형별, 2020-2034년
- 중동 및 아프리카 : 치료 유형별, 2020-2034년
- 중동 및 아프리카 : 최종사용자별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 질병 유형별, 2020-2034년
- 라틴아메리카 : 치료 유형별, 2020-2034년
- 라틴아메리카 : 최종사용자별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 프로파일
- Alexion Pharmaceuticals, Inc.
- Amicus Therapeutics, Inc.
- BioMarin Pharmaceutical Inc.
- Eli Lilly and Company
- Johnson & Johnson(Actelion Pharmaceuticals Ltd.)
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi(Genzyme Corporation)
- Sigilon Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited(Shire Plc)
- Chiesi Farmaceutici SpA
The lysosomal storage disease treatment market size is expected to reach USD 6.80 Billion by 2034, according to a new study by Polaris Market Research. The report "Lysosomal Storage Disease Treatment Market Size, Share, Trends, & Industry Analysis Report By Disease Type (Gaucher's Diseases, Fabry Diseases, Pompe's Syndrome, Mucopolysaccharidosis, and Others), By Type of Therapy, By End User, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The lysosomal storage disease (LSD) treatment market is witnessing steady progress as pharmaceutical companies and research institutions develop new therapies aimed at addressing rare genetic disorders. Growing awareness, increasing patient advocacy, and supportive regulatory frameworks are helping accelerate drug approvals and improve access to innovative treatments.
Rising investments in biotechnology and personalized medicine are shifting the market focus beyond symptom control toward long-term disease management and the development of potential cures. This evolution reflects a strong push toward improving patient outcomes and delivering more effective, targeted therapies for conditions such as Gaucher disease, Fabry disease, and Pompe disease.
Lysosomal Storage Disease Treatment Market Report Highlights
Based on disease type, gaucher's disease segment dominated the market in 2024, driven by its wider global prevalence and the presence of an established therapeutic ecosystem.
In terms of type of therapy, the enzyme replacement therapy (ERT) segment dominated the market in 2024. This is driven by the increasing adoption in managing various lysosomal storage disorders.
In terms of end user, the hospital segment dominated the market in 2024, attributed to delivery of specialized interventions such as enzyme replacement therapies and stem cell-based procedures.
North America accounted for the majority share of 36.98 in the global lysosomal storage disease treatment market in 2024, due to the strong presence of biotech and pharmaceutical firms advancing treatments for rare genetic conditions.
Asia Pacific held 6.13% market share, owing to ongoing improvements in healthcare infrastructure and access to advanced diagnostic capabilities.
A few global key market players include Alexion Pharmaceuticals, Inc., Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc., Eli Lilly and Company, Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi (Genzyme Corporation), Sigilon Therapeutics, Inc., Takeda Pharmaceutical Company Limited (Shire Plc), Chiesi Farmaceutici S.p.A., Orphazyme A/S, Protalix BioTherapeutics, Inc., and Ultragenyx Pharmaceutical Inc.
Polaris Market Research has segmented the market report on the basis of disease type, type of therapy, end user, and region:
By Disease Type Outlook (Revenue, USD Billion, 2020-2034)
Gaucher's Diseases
Fabry Diseases
Pompe's Syndrome
Mucopolysaccharidosis
Others
By Type of Therapy Outlook (Revenue, USD Billion, 2020-2034)
Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Others
By End User Outlook (Revenue, USD Billion, 2020-2034)
Hospitals
Clinics
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Lysosomal Storage Disease Treatment Market Insights
- 4.1. Lysosomal Storage Disease Treatment Market - Market Snapshot
- 4.2. Lysosomal Storage Disease Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Incidence of Rare Genetic Disorders
- 4.2.1.2. Advancements in Enzyme Replacement Therapy (ERT)
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Treatment Costs and Limited Reimbursement
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Lysosomal Storage Disease Treatment Market Trends
- 4.6. Value Chain Analysis
5. Global Lysosomal Storage Disease Treatment Market, by Disease Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 5.3. Gaucher's Diseases
- 5.3.1. Global Lysosomal Storage Disease Treatment Market, by Gaucher's Diseases, by Region, 2020-2034 (USD Billion)
- 5.4. Fabry Diseases
- 5.4.1. Global Lysosomal Storage Disease Treatment Market, by Fabry Diseases, by Region, 2020-2034 (USD Billion)
- 5.5. Pompe's Syndrome
- 5.5.1. Global Lysosomal Storage Disease Treatment Market, by Pompe's Syndrome, by Region, 2020-2034 (USD Billion)
- 5.6. Mucopolysaccharidosis
- 5.6.1. Global Lysosomal Storage Disease Treatment Market, by Mucopolysaccharidosis, by Region, 2020-2034 (USD Billion)
- 5.7. Others
- 5.7.1. Global Lysosomal Storage Disease Treatment Market, by Others, by Region, 2020-2034 (USD Billion)
6. Global Lysosomal Storage Disease Treatment Market, by Type of Therapy
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 6.3. Enzyme Replacement Therapy
- 6.3.1. Global Lysosomal Storage Disease Treatment Market, by Enzyme Replacement Therapy, by Region, 2020-2034 (USD Billion)
- 6.4. Stem Cell Therapy
- 6.4.1. Global Lysosomal Storage Disease Treatment Market, by Stem Cell Therapy, by Region, 2020-2034 (USD Billion)
- 6.5. Substrate Reduction Therapy
- 6.5.1. Global Lysosomal Storage Disease Treatment Market, by Substrate Reduction Therapy, by Region, 2020-2034 (USD Billion)
- 6.6. Others
- 6.6.1. Global Lysosomal Storage Disease Treatment Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Lysosomal Storage Disease Treatment Market, by End User
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 7.3. Hospitals
- 7.3.1. Global Lysosomal Storage Disease Treatment Market, by Hospitals, by Region, 2020-2034 (USD Billion)
- 7.4. Clinics
- 7.4.1. Global Lysosomal Storage Disease Treatment Market, by Clinics, by Region, 2020-2034 (USD Billion)
- 7.5. Others
- 7.5.1. Global Lysosomal Storage Disease Treatment Market, by Others, by Region, 2020-2034 (USD Billion)
8. Global Lysosomal Storage Disease Treatment Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Lysosomal Storage Disease Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
- 8.3. Lysosomal Storage Disease Treatment Market - North America
- 8.3.1. North America: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.3.3. North America: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.3.4. Lysosomal Storage Disease Treatment Market - U.S.
- 8.3.4.1. U.S.: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.3.4.2. U.S.: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.3.4.3. U.S.: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.3.5. Lysosomal Storage Disease Treatment Market - Canada
- 8.3.5.1. Canada: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4. Lysosomal Storage Disease Treatment Market - Europe
- 8.4.1. Europe: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.3. Europe: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4.4. Lysosomal Storage Disease Treatment Market - UK
- 8.4.4.1. UK: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4.5. Lysosomal Storage Disease Treatment Market - France
- 8.4.5.1. France: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.5.2. France: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.5.3. France: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4.6. Lysosomal Storage Disease Treatment Market - Germany
- 8.4.6.1. Germany: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4.7. Lysosomal Storage Disease Treatment Market - Italy
- 8.4.7.1. Italy: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4.8. Lysosomal Storage Disease Treatment Market - Spain
- 8.4.8.1. Spain: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4.9. Lysosomal Storage Disease Treatment Market - Netherlands
- 8.4.9.1. Netherlands: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4.10. Lysosomal Storage Disease Treatment Market - Russia
- 8.4.10.1. Russia: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.4.11. Lysosomal Storage Disease Treatment Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5. Lysosomal Storage Disease Treatment Market - Asia Pacific
- 8.5.1. Asia Pacific: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5.4. Lysosomal Storage Disease Treatment Market - China
- 8.5.4.1. China: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.4.2. China: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.4.3. China: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5.5. Lysosomal Storage Disease Treatment Market - India
- 8.5.5.1. India: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.5.2. India: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.5.3. India: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5.6. Lysosomal Storage Disease Treatment Market - Malaysia
- 8.5.6.1. Malaysia: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5.7. Lysosomal Storage Disease Treatment Market - Japan
- 8.5.7.1. Japan: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5.8. Lysosomal Storage Disease Treatment Market - Indonesia
- 8.5.8.1. Indonesia: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5.9. Lysosomal Storage Disease Treatment Market - South Korea
- 8.5.9.1. South Korea: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5.10. Lysosomal Storage Disease Treatment Market - Australia
- 8.5.10.1. Australia: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.5.11. Lysosomal Storage Disease Treatment Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.6. Lysosomal Storage Disease Treatment Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.6.4. Lysosomal Storage Disease Treatment Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.6.5. Lysosomal Storage Disease Treatment Market - UAE
- 8.6.5.1. UAE: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.6.6. Lysosomal Storage Disease Treatment Market - Israel
- 8.6.6.1. Israel: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.6.7. Lysosomal Storage Disease Treatment Market - South Africa
- 8.6.7.1. South Africa: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.6.8. Lysosomal Storage Disease Treatment Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.7. Lysosomal Storage Disease Treatment Market - Latin America
- 8.7.1. Latin America: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.7.4. Lysosomal Storage Disease Treatment Market - Mexico
- 8.7.4.1. Mexico: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.7.5. Lysosomal Storage Disease Treatment Market - Brazil
- 8.7.5.1. Brazil: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.7.6. Lysosomal Storage Disease Treatment Market - Argentina
- 8.7.6.1. Argentina: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
- 8.7.7. Lysosomal Storage Disease Treatment Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Lysosomal Storage Disease Treatment Market, by Disease Type, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Lysosomal Storage Disease Treatment Market, by Type of Therapy, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Lysosomal Storage Disease Treatment Market, by End User, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Alexion Pharmaceuticals, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Disease Type Benchmarking
- 10.1.4. Recent Development
- 10.2. Amicus Therapeutics, Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Disease Type Benchmarking
- 10.2.4. Recent Development
- 10.3. BioMarin Pharmaceutical Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Disease Type Benchmarking
- 10.3.4. Recent Development
- 10.4. Eli Lilly and Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Disease Type Benchmarking
- 10.4.4. Recent Development
- 10.5. Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Disease Type Benchmarking
- 10.5.4. Recent Development
- 10.6. Merck & Co., Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Disease Type Benchmarking
- 10.6.4. Recent Development
- 10.7. Novartis AG
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Disease Type Benchmarking
- 10.7.4. Recent Development
- 10.8. Pfizer Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Disease Type Benchmarking
- 10.8.4. Recent Development
- 10.9. Sanofi (Genzyme Corporation)
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Disease Type Benchmarking
- 10.9.4. Recent Development
- 10.10. Sigilon Therapeutics, Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Disease Type Benchmarking
- 10.10.4. Recent Development
- 10.11. Takeda Pharmaceutical Company Limited (Shire Plc)
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Disease Type Benchmarking
- 10.11.4. Recent Development
- 10.12. Chiesi Farmaceutici S.p.A.
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Disease Type Benchmarking
- 10.12.4. Recent Development
샘플 요청 목록